FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, I | D.C. 20549 |
|---------------|------------|
|---------------|------------|

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Heron Patrick J | | | | 2. Issuer Name and Ticker or Trading Symbol Arcutis Biotherapeutics, Inc. [ARQT] | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | | | |
|--|----------------------|---|--|--|--|---|-----------------------|---|---|-----------------------|--|--|---|---------------|--|---|--------|--|
| (Last) (First) (Middle) | | | | 3. Date of Earliest Transaction (Month/Day/Year) 03/04/2024 | | | | | | | Officer below) | | | | Other (specify pelow) | | | |
| C/O ARCUTIS BIOTHERAPEUTICS, INC. 3027 TOWNSGATE ROAD, SUITE 300 | | | | 4. If | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person | | | | | | |
| (Street) WESTLAKE | | | | | | | | | | | Form filed by More than One Reporting Person | | | | | | | |
| VILLAC | VILLAGE CA 91361 | | | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | | | |
| (City) | (City) (State) (Zip) | | | | Check t satisfy t | this box to in the affirmati | ndicate t ve defer | hat a tr | ransaction was nditions of Rule | made pt 10b5-1(d | rsuant to a | a contract, instruct truction 10. | ction o | r written pla | an that | is intend | ded to | |
| | | Table | I - N | lon-Deriva | tive | Secu | rities A | cquir | ed, D | isposed o | of, or | Benefic | cially Owne | d | | | | |
| Date | | 2. Transaction Date (Month/Day/Ye | | 2A. Deemed Execution Date, if any (Month/Day/Year) | | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (AD Disposed Of (D) (Instr. 3 and 5) | | | 5. Amount of Securities Beneficially Owned Follow | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | | |
| | | | | | | | Code | v | Amount | (A) or (D) | Price | Reported Transaction(s) (Instr. 3 and 4) | | | | (Instr. 4) | | |
| Common Stock 02 | | | 03/04/202 | 04/2024 | | P | | | 21,052 | A | \$9.5 | 8,785,284 | | | | By Frazier Life Sciences VIII, L.P. ⁽¹⁾ | | |
| Common Stock | | | | | | | | | | | | 7 | | I | | By Fl Life Scien VIII, | | |
| Common Stock | | | | | | | | | | | 23,688 | } | I | | | | | |
| Common Stock | | | | | | | | | | 8,687(4) | | D | | | | | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | |
| Derivative Conversion Date Execution Date, | | Code | Transaction of Code (Instr. Derivative | | Expiration (Month/Da | | | Amo Secu Unde Deriv | le and unt of urities erlying rative urity (Instr. | Owne Follo Repo | | rative or initial variety of initial variety or ini | | : ' | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| Evolanatio | | | | | Code | e V | (A) (D | Date) Exe | e rcisab | Expiration le Date | n Title | Amount or Number of Shares | 1 1 | | | | | |

- 1. The shares are held directly by Frazier Life Sciences VIII, L.P. FHM Life Sciences VIII, L.P. is the general partner of Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, L.L.C. is the general partner of FHM Life Sciences VIII, L.P. James N. Topper and the Reporting Person are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences VIII, L.P. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- 2. The shares are held directly by FHM Life Sciences VIII, L.L.C. James N. Topper and the Reporting Person are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences VIII, L.P. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- 3. The shares are held directly by The Heron Living Trust 11/30/2004. The Reporting Person is the co-trustee of The Heron Living Trust 11/30/2004 and has voting and investment power of the securities held by The Heron Living Trust 11/30/2004.
- 4. Includes 4,375 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of the Issuer's Common Stock for each one (1) RSU upon the vesting thereof.

/s/ Steve R. Bailey, Attorneyin-Fact For Patrick J. Heron

03/06/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.